Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | NB4 is a human acute promyelocytic leukemia (APL; AML FAB M3 subtype) cell line, established in 1989 from a bone marrow sample taken from a 23-year-old Caucasian female patient during her second relapse. This cell line serves as a reference model for studying the PML–RARA fusion oncoprotein, which arises from the t(15;17)(q22;q11–12) translocation. NB4 cells grow in suspension and exhibit a round, pleomorphic morphology; upon treatment with all-trans retinoic acid (ATRA), they undergo terminal differentiation into granulocytes—a process that forms the molecular basis for differentiation therapy in APL. Their immunophenotype is characteristic of immature myeloid cells, expressing CD13, CD33, CD11b, CD4, and CD5, while lacking the expression of CD34 and HLA-DR. ATRA-resistant sublines derived from NB4 (such as NB4-LR1 and NB4-AsR) are essential tools for investigating defects in retinoic acid signaling. NB4 cells are widely used in research concerning ATRA- and arsenic-induced differentiation, resistance to retinoic acid, and targeted therapies directed against the PML–RARA fusion protein. |
| Tissue | Bone marrow (in situ, at second relapse) |
| Disease | Acute Promyelocytic Leukemia (APL; AML FAB M3) |
| Morphology | Round cells, single, polymorphic; occasional giant cells |
| Gender | Female |
| Age | 23 years |
| Ethnicity | Caucasian |
| Product Format | Frozen |
| Growth Mode | Suspension |
| Biosafety Level | 1 (Biosafety classification is based on U.S. Public Health Service Guidelines) |
| Applications | 1. Study of PML–RARA fusion function in acute promyelocytic leukemia 2. All-trans retinoic acid (ATRA)- and arsenic trioxide-induced differentiation and apoptosis 3. Mechanisms of retinoic acid resistance and differentiation therapy 4. Transcriptional and epigenetic regulation of leukemogenesis 5. Pharmacogenomic and CRISPR functional-genomic screening (CCLE, GDSC, DepMap, LL-100) 6. In vivo leukemia modeling in SCID mice |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Tumorigenic | Yes; intraperitoneal inoculation of 1 × 10⁶ cells induces ascitic tumors in 100% of SCID mice |
| Karyotype | Human hyper-triploid; modal number 78 (range 71–81) with t(15;17)(q22;q11-12) and multiple derivative chromosomes |
| Mycoplasma Test | Negative |
| Viral Status | Negative for EBV, HBV, HCV, HHV-8, HIV-1, HIV-2, HTLV-1/2, MLV and SMRV; reverse transcriptase negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Collect the cell suspension into a centrifuge tube and centrifuge at approximately 200 × g for 5 minutes. 2. Carefully discard the supernatant. 3. Resuspend the cell pellet in fresh complete growth medium and gently pipette to break up any cell aggregates. 4. Count the cells and adjust to the recommended seeding density with fresh medium. 5. Aliquot the cell suspension into new culture vessels. |
| Medium Renewal | 2 to 3 times per week |
| Subcultivation Ratio | Maintain at 0.5-1.0 × 10⁶ cells/mL; split at a ratio of 1:2 to 1:3 every 2 to 3 days. |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | 70% complete growth medium + 20% FBS + 10% DMSO |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RO01208 | Cas9 Stable Cell Line - NB4 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.